[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100068310":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":16,"responsibleParty":7,"collaborators":7,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":7,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":7,"enrollmentInfo":84,"targetDuration":7,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":7,"overallStatus":92,"whyStopped":7,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Pfizer","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Pregabalin",[13],{"name":14,"affiliation":5,"role":15},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[17,30,38,46,55,64,73],{"facility":18,"status":7,"city":19,"state":20,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":7},"Pfizer Investigational Site","Little Bay","New South Wales","2036","Australia","AU",{"type":25,"coordinates":26},"Point",[27,28],151.24299,-33.97899,{"lat":28,"lon":27},{"facility":18,"status":7,"city":31,"state":20,"zip":32,"country":22,"countryCode":23,"cosmosGeoPoint":33,"geoPoint":37,"contacts":7},"St Leonards","2065",{"type":25,"coordinates":34},[35,36],151.19836,-33.82344,{"lat":36,"lon":35},{"facility":18,"status":7,"city":39,"state":20,"zip":40,"country":22,"countryCode":23,"cosmosGeoPoint":41,"geoPoint":45,"contacts":7},"Warrawong","2502",{"type":25,"coordinates":42},[43,44],150.88833,-34.485,{"lat":44,"lon":43},{"facility":18,"status":7,"city":47,"state":48,"zip":49,"country":22,"countryCode":23,"cosmosGeoPoint":50,"geoPoint":54,"contacts":7},"Woolloongabba","Queensland","4102",{"type":25,"coordinates":51},[52,53],153.03655,-27.48855,{"lat":53,"lon":52},{"facility":18,"status":7,"city":56,"state":57,"zip":58,"country":22,"countryCode":23,"cosmosGeoPoint":59,"geoPoint":63,"contacts":7},"Heidelberg","Victoria","3084",{"type":25,"coordinates":60},[61,62],145.06667,-37.75,{"lat":62,"lon":61},{"facility":18,"status":7,"city":65,"state":66,"zip":67,"country":22,"countryCode":23,"cosmosGeoPoint":68,"geoPoint":72,"contacts":7},"Shenton Park","Western Australia","6008",{"type":25,"coordinates":69},[70,71],115.79807,-31.95575,{"lat":71,"lon":70},{"facility":18,"status":7,"city":74,"state":7,"zip":7,"country":22,"countryCode":23,"cosmosGeoPoint":7,"geoPoint":7,"contacts":7},"NSW","100068310","phase-3-to-evaluate-long-term-safety-and-efficacy-of-pregabalin-in-the-treatment-of-neuropathic-pain-after-spinal-cord-injury-100068310",false,"NCT00141375","To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.","An Open-Label Extension to Evaluate the Safety and Efficacy of Pregabalin for Treatment of Chronic Central Neuropathic Pain After Spinal Cord Injury.","Inclusion Criteria:\n\n* Must have met the inclusion criteria of the preceding double-blind BID study in central pain following spinal cord injury.\n* Must have received study medication under double-blind conditions.\n\nExclusion Criteria:\n\n* Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.","ALL","18 Years",{"count":85,"type":7},132,"INTERVENTIONAL",[88],"PHASE3","To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain after spinal cord injury.",[91],"Neuropathic Pain","COMPLETED","2008-01-09",{"date":95,"type":96},"2008-01-15","ESTIMATED",{"date":98,"type":7},"2002-08",{"date":100,"type":101},"2006-01","ACTUAL",{"name":5,"class":6},7]